Saccharomyces cerevisiae-based probiotic as novel anti-microbial agent for therapy of bacterial vaginosis

Virulence. 2018 Dec 31;9(1):954-966. doi: 10.1080/21505594.2018.1464362.

Abstract

In this study, we demonstrate, for the first time, that Saccharomyces cerevisiae-based probiotic shows an inhibitory effect on Gardnerella vaginalis infection. This effect is likely due to several actions: direct interference with adherence to vaginal tissues, inhibition of sialidase activity, reduction of vaginal epithelial exfoliation. Gardnerella vaginalis does not induce vaginal inflammation and no inflammatory cytokines were, indeed, produced, by the mouse vagina, neither by Gardnerella vaginalis and by the probiotic. Collectively, our data incite to further investigations on Saccharomyces cerevisiae probiotic as a potential prophylactic or therapeutic agent in the vaginosis caused by Gardnerella vaginalis.

Keywords: G. vaginalis; S. cerevisiae; adherence; bacterial vaginosis; displacement; exfoliation; probiotic; sialidase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibiosis
  • Female
  • Gardnerella vaginalis / physiology*
  • Gram-Positive Bacterial Infections / drug therapy*
  • Gram-Positive Bacterial Infections / microbiology
  • Humans
  • Mice
  • Mice, Inbred C57BL
  • Probiotics / administration & dosage*
  • Saccharomyces cerevisiae / physiology*
  • Vagina / microbiology
  • Vaginosis, Bacterial / drug therapy*
  • Vaginosis, Bacterial / microbiology

Grants and funding

This work was realized in the frame of service agreement supported by Lesaffre International.